New combination of oral drugs effective against the virus of hepatitis C in patients with HIV

12 02 2015

Between 130 y 150 millones de personas en el mundo están infectadas por el virus de la hepatitis C (HCV) y, of these, around 5 millions are also by the HIV virus. A study published in the prestigious journalThe Lancetdemonstrates efficacy in the treatment of HCV in patients co-infected with HIV with the combined use of two drugs administered oral or mono during 12 weeks. This work has involved Dr. Josep Mallolas, consultant service of infectious diseases at the Hospital Clinic and research the Group IDIBAPS infectious diseases and AIDS. The Clinic has been the only Spanish Center who participated in this study.

All patients with HCV, both infected monkey as co-infected by HIV, they are at risk of the complications arising from the disease and end up requiring a liver transplant. In addition, in patients with HIV viral load is high, the disease progresses more rapidly and there are fewer treatment options.

In this international multicenter phase II study were administered antiviral two,grazoprevir and elbasvir, with or without Ribavirin, during 8 o 12 weeks to 218 hepatitis C in previously untreated patients (159 with HCV and 59 co-infected by HIV). Administer this treatment in parallel with mono and co-infected patients is innovative, Since patients with HIV are often involved in independent clinical trials. Like this, This is a unique opportunity to determine role for HIV infection in response to HCV treatment.

The results indicate that the therapeutic regimen was well tolerated and, past the 12 weeks, between the 87 and the 98% participants in the study had a number of hepatitis C virus RNA lower to 25 IU/ml, indicating a virological response sustained or, What is the same, cured hepatitis C. This response was similar both for mono infected as the co-infected patients, suggesting that this combination of drugs provides a safe and effective treatment option for the two groups of patients.

With these promising results of treatment of hepatitis with only 12 weeks of treatment and with a very good tolerance, they have already launched several phase III clinical trials that evaluated the effectiveness of this therapeutic guideline in one larger number of patients.

The article reference:

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 Mono-infection and HIV/hepatitis C virus co-infection (C WORTHY): a randomised, open-label phase 2 trial

SULKOWSKI M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahas Are, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman and, F Dutko, M Shaughnessy, Hwang P, Howe AY, J Wahl, M Robertson, Barr E, Have B.

Lancet. 2014 Nov 11. PII: S0140-6736(14)61793-1. DOI: 10.1016/S0140-6736(14)61793-1. [Epub ahead of print] [en línea] Barcelona (ESP):, 12 de febrero de 2015 [REF. 20 in January of 2015] Available on Internet:



Leave a comment

You can use these tags : <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>